<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03953183</url>
  </required_header>
  <id_info>
    <org_study_id>P3P-SE-02-RU</org_study_id>
    <nct_id>NCT03953183</nct_id>
  </id_info>
  <brief_title>Product Use and Adaptation, Safety and Tolerability of P3P in Adult Healthy Smokers Switching to it</brief_title>
  <official_title>A Randomized, Double-blinded, 2-arm Parallel Groups, Single Center Study to Assess Product Use and Adaptation, Safety and Tolerability of P3P, a Novel Nicotine-containing Product, in Adult Healthy Cigarette Smokers Switching to One of Two P3P Variants for One Month</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philip Morris Products S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philip Morris Products S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the product use and adaptation in adult, current&#xD;
      cigarette smoking subjects between baseline and after one month of use of one of two P3P&#xD;
      variants. The effect of P3P use behavior on nicotine pharmacokinetic (PK) profile,&#xD;
      acceptability, as well as the safety and tolerability of P3P over a period of 1 month will be&#xD;
      investigated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study of daily use of up to 15 P3P products over one month, including 2 confinement&#xD;
      periods (2 overnight stays at the beginning of the study and 1 overnight stay at the end of&#xD;
      the exposure period). During the confinement visits, nicotine PK from P3P exposure will be&#xD;
      assessed as well as pharmacodynamic effects related to craving, sensory parameters, product&#xD;
      experience, and product acceptance.&#xD;
&#xD;
      Between the two confinement periods, subjects will return to the investigational site for&#xD;
      weekly ambulatory visits during which P3P will be resupplied and selected safety and other&#xD;
      study assessments will be performed.&#xD;
&#xD;
      From the start of the exposure period onwards, subjects will be instructed not to smoke or&#xD;
      use other tobacco or nicotine containing products and to use P3P exclusively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 23, 2019</start_date>
  <completion_date type="Actual">October 25, 2019</completion_date>
  <primary_completion_date type="Actual">August 14, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomized, double-blinded, 2-arm parallel groups, single center study</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Neither the site staff nor the subject will be informed about the product variant the subjects have been randomized to.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Nicotine Concentration-time Profile</measure>
    <time_frame>Derived from multiple blood sampling pre- and post-product use (over 4 hours post-product use), on day 1 and day 30.</time_frame>
    <description>To measure the plasma nicotine concentration-time profile following correction of baseline nicotine levels.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Nicotine Concentration [cCmax]</measure>
    <time_frame>Derived from multiple blood sampling pre- and post-product use (over 4 hours post-product use), on day 1 and day 30.</time_frame>
    <description>To measure the maximum plasma nicotine concentration [cCmax] following correction of baseline nicotine levels.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to the Maximum Nicotine Concentration [cTmax]</measure>
    <time_frame>Derived from multiple blood sampling pre- and post-product use (over 4 hours post-product use), on day 1 and day 30.</time_frame>
    <description>To measure the time to maximum nicotine concentration [cTmax] following correction of baseline nicotine levels.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve From Start of Product Use (T0) to 4 Hours [cAUC(0-4h)]</measure>
    <time_frame>Derived from multiple blood sampling pre- and post-product use (over 4 hours post-product use), on day 1 and day 30.</time_frame>
    <description>To measure the area under the plasma concentration-time curve [cAUC(0-4h)] following correction of baseline nicotine levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Craving for a Cigarette</measure>
    <time_frame>Before, during and up to 4 hours post-product use on day 1 and day 30</time_frame>
    <description>Measured on a Visual Analogue Scale (VAS) of 0 (no craving) to 100 (strong craving). Over time results calculated as area under curve mm*hour.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensory Parameters</measure>
    <time_frame>Within 60 minutes after product use on day 1 and day 30.</time_frame>
    <description>Measured with a Sensory Questionnaire. Response to each question is assessed on a 7-point scale, ranging from 1 (not at all) to 7 (extremely).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Experience</measure>
    <time_frame>Within 60 minutes after product use on day 1 and day 30.</time_frame>
    <description>Measured with ABOUT[TM]-Product Experience questionnaire. Response to each question is assessed on a 7-point scale, ranging from 1 (not at all) to 7 (extremely).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Dependence</measure>
    <time_frame>Within 60 minutes after product use on day 1 and day 30.</time_frame>
    <description>Measured with ABOUT[TM]-Dependence questionnaire. Response to each question is assessed on a 5-point scale, ranging from 1 (not at all/never) to 5 (extremely/all the time) or a 6-point scale ranging from 0 (more than 3 hours) to 5 (0-5 minutes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptance</measure>
    <time_frame>Within 60 minutes after product use on day 1 and day 30.</time_frame>
    <description>Measured with a Product Acceptance questionnaire. Response to each question is assessed on a 7-point scale, ranging from 1 (most negative) to 7 (most positive) or as multiple choice questions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Puffing Behavior of Subject</measure>
    <time_frame>Evaluated by site staff on day 1 and day 30. Self-evaluated by subject on day 2, day 7, day 15, day 22, and day 29.</time_frame>
    <description>To measure changes in subject puffing behavior. Evaluated by selection of one puffing behavior response out of three possible responses.&#xD;
1. Puffing and holding the aerosol in the mouth for a short time and then inhaling (i.e. like a cigarette)&#xD;
2. Puffing and immediately inhaling (without holding the aerosol in the mouth)&#xD;
3. Puffing and immediately exhaling, without inhalation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Product Use</measure>
    <time_frame>Recorded daily by subject, in product use diary, from day 1 until day 30.</time_frame>
    <description>To assess the number of any nicotine/tobacco products used overall on a daily basis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NEQ</measure>
    <time_frame>Measured at baseline, day 7, day 15, day 22, and day 29.</time_frame>
    <description>To measure percent changes from baseline in Nicotine equivalents (NEQ) concentrations, measured in spot urine and expressed as concentration adjusted for creatinine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total NNAL</measure>
    <time_frame>Measured at baseline, day 7, day 15, day 22, and day 29.</time_frame>
    <description>To measure percent changes from baseline in total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) concentrations, measured in spot urine and expressed as concentration adjusted for creatinine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CEMA</measure>
    <time_frame>Measured at baseline, day 7, day 15, day 22, and day 29.</time_frame>
    <description>To measure percent changes from baseline in 2-cyanoethylmercapturic acid (CEMA) concentrations, measured in spot urine and expressed as concentration adjusted for creatinine (ng/mg creat).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CYP2A6 Activity</measure>
    <time_frame>Measured before product use, on day 1 and day 30.</time_frame>
    <description>To measure percent change from baseline in CYP2A6 enzymatic activity, on day 30, as measured by molar metabolic ratio of trans-3-hydroxy-cotinine/cotinine in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Powder Extracted From P3P Used for PK Assessment.</measure>
    <time_frame>Before and after product use, on day 1 and day 30.</time_frame>
    <description>Weight difference (mg) of P3P before and after use, to determine the amount of powder extracted from P3P.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>P3P-1mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects randomized to exclusive use of P3P-1mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P3P-2mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects randomized to exclusive use of P3P-2mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>P3P-1mg</intervention_name>
    <description>P3P-1mg (P3P product containing 1mg of nicotine.)</description>
    <arm_group_label>P3P-1mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>P3P-2mg</intervention_name>
    <description>P3P-2mg (P3P product containing 2mg of nicotine.)</description>
    <arm_group_label>P3P-2mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has signed and dated the ICF and is able to understand the information&#xD;
             provided in it.&#xD;
&#xD;
          -  Subject has been a smoker for at least the last 3 years prior to the Screening Visit&#xD;
             and has smoked 5 to 15 commercially available cigarettes per day for the last 3 months&#xD;
             prior to Screening.&#xD;
&#xD;
          -  Subject has a positive urinary cotinine test (cotinine ≥ 200 ng/mL).&#xD;
&#xD;
          -  Subject does not plan to quit smoking within 2 months.&#xD;
&#xD;
          -  Smoking, healthy subject as judged by the Investigator or designee based on available&#xD;
             assessments from the Screening period.&#xD;
&#xD;
          -  Ready to switch from smoking cigarettes to using P3P for the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  As per the Investigator's judgment, the subject cannot participate in the study for&#xD;
             any reason other than medical (e.g., psychological and/or social reason).&#xD;
&#xD;
          -  Subject has a clinically relevant disease which requires medication or any other&#xD;
             clinically significant medical condition, which as per the judgment of the&#xD;
             Investigator would jeopardize the safety of the subject.&#xD;
&#xD;
          -  Subject has asthma condition (post-bronchodilator FEV1/FVC &lt; 0.75 and reversibility in&#xD;
             FEV1 ≥ 12% and &gt; 200 mL from pre- to post-bronchodilator values).&#xD;
&#xD;
          -  Subject has (FEV1/FVC) &lt; 0.7 and FEV1 &lt; 80% predicted value at post-bronchodilator&#xD;
             spirometry.&#xD;
&#xD;
          -  Subject has a BMI &lt; 18.5 kg/m2 or &gt; 32.0 kg/m2.&#xD;
&#xD;
          -  Subject has received medication within 14 days or within 5 half-lives of the drug&#xD;
             prior to Admission (whichever is longer) which has an impact on CYP2A6 activity.&#xD;
&#xD;
          -  Subject has a positive serology test for HIV 1/2, Hepatitis B, or Hepatitis C.&#xD;
&#xD;
          -  Subject has a positive alcohol breath test and/or a history of alcohol disorder within&#xD;
             the past 2 years.&#xD;
&#xD;
          -  Subject has a positive urine drug test.&#xD;
&#xD;
          -  Subject has participated in another clinical study within 3 months prior to the&#xD;
             Screening Visit.&#xD;
&#xD;
          -  Subject has been previously screened or enrolled in this study.&#xD;
&#xD;
          -  For women only: subject is pregnant or is breastfeeding.&#xD;
&#xD;
          -  For women of childbearing potential only: subject does not agree to use an acceptable&#xD;
             method of effective contraception.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christelle Haziza, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Philip Morris Products SA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vasilyuk V Bogdanovich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LLC Scientific Research Center Eco-Safety</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LLC Scientific Research Center Eco-Safety</name>
      <address>
        <city>St. Petersburg</city>
        <zip>196143</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <reference>
    <citation>Chrea C, Acquadro C, Afolalu EF, Spies E, Salzberger T, Abetz-Webb L, Cano S, Arnould B, Mainy N, Rose J, Weitkunat R. Developing fit-for-purpose self-report instruments for assessing consumer responses to tobacco and nicotine products: the ABOUT™ Toolbox initiative. F1000Res. 2018 Dec 2;7:1878. doi: 10.12688/f1000research.16810.1. eCollection 2018.</citation>
    <PMID>30906527</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 15, 2019</study_first_submitted>
  <study_first_submitted_qc>May 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2019</study_first_posted>
  <results_first_submitted>November 17, 2020</results_first_submitted>
  <results_first_submitted_qc>November 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 14, 2020</results_first_posted>
  <last_update_submitted>November 17, 2020</last_update_submitted>
  <last_update_submitted_qc>November 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nicotine</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 12, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT03953183/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 24, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT03953183/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>P3P-1mg</title>
          <description>Subjects randomized to exclusive use of P3P-1mg&#xD;
P3P-1mg: P3P-1mg (P3P product containing 1mg of nicotine.)</description>
        </group>
        <group group_id="P2">
          <title>P3P-2mg</title>
          <description>Subjects randomized to exclusive use of P3P-2mg&#xD;
P3P-2mg: P3P-2mg (P3P product containing 2mg of nicotine.)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>P3P-1mg</title>
          <description>Subjects randomized to exclusive use of P3P-1mg&#xD;
P3P-1mg: P3P-1mg (P3P product containing 1mg of nicotine.)</description>
        </group>
        <group group_id="B2">
          <title>P3P-2mg</title>
          <description>Subjects randomized to exclusive use of P3P-2mg&#xD;
P3P-2mg: P3P-2mg (P3P product containing 2mg of nicotine.)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.3" spread="4.82"/>
                    <measurement group_id="B2" value="30.0" spread="8.36"/>
                    <measurement group_id="B3" value="28.2" spread="7.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="174" spread="9.49"/>
                    <measurement group_id="B2" value="172" spread="12.5"/>
                    <measurement group_id="B3" value="173" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.3" spread="3.69"/>
                    <measurement group_id="B2" value="24.0" spread="3.48"/>
                    <measurement group_id="B3" value="23.7" spread="3.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Plasma Nicotine Concentration-time Profile</title>
        <description>To measure the plasma nicotine concentration-time profile following correction of baseline nicotine levels.</description>
        <time_frame>Derived from multiple blood sampling pre- and post-product use (over 4 hours post-product use), on day 1 and day 30.</time_frame>
        <population>Some participants were excluded from analysis for protocol deviations. For participants in whom the elimination rate constant could not be calculated for any of the visits, background-corrected nicotine concentrations were considered as missing.</population>
        <group_list>
          <group group_id="O1">
            <title>P3P-1mg</title>
            <description>Subjects randomized to exclusive use of P3P-1mg&#xD;
P3P-1mg: P3P-1mg (P3P product containing 1mg of nicotine.)</description>
          </group>
          <group group_id="O2">
            <title>P3P-2mg</title>
            <description>Subjects randomized to exclusive use of P3P-2mg&#xD;
P3P-2mg: P3P-2mg (P3P product containing 2mg of nicotine.)</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Nicotine Concentration-time Profile</title>
          <description>To measure the plasma nicotine concentration-time profile following correction of baseline nicotine levels.</description>
          <population>Some participants were excluded from analysis for protocol deviations. For participants in whom the elimination rate constant could not be calculated for any of the visits, background-corrected nicotine concentrations were considered as missing.</population>
          <units>ng/ml</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 mins after start of product use (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.563" lower_limit="0.384" upper_limit="0.824"/>
                    <measurement group_id="O2" value="0.563" lower_limit="0.370" upper_limit="0.858"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 mins after start of product use (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.928" lower_limit="0.635" upper_limit="1.36"/>
                    <measurement group_id="O2" value="1.02" lower_limit="0.688" upper_limit="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 mins after start of product use (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.982" lower_limit="0.699" upper_limit="1.38"/>
                    <measurement group_id="O2" value="1.39" lower_limit="0.949" upper_limit="2.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 mins after start of product use (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.18" lower_limit="0.914" upper_limit="1.54"/>
                    <measurement group_id="O2" value="1.58" lower_limit="1.14" upper_limit="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 mins after start of product use (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.24" lower_limit="0.969" upper_limit="1.60"/>
                    <measurement group_id="O2" value="1.59" lower_limit="1.09" upper_limit="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr after start of product use (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" lower_limit="0.850" upper_limit="1.34"/>
                    <measurement group_id="O2" value="1.45" lower_limit="1.04" upper_limit="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hr after start of product use (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.702" lower_limit="0.546" upper_limit="0.904"/>
                    <measurement group_id="O2" value="1.08" lower_limit="0.824" upper_limit="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hr after start of product use (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.353" lower_limit="0.272" upper_limit="0.458"/>
                    <measurement group_id="O2" value="0.570" lower_limit="0.416" upper_limit="0.781"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 mins after start of product use (Day 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" lower_limit="0.784" upper_limit="1.31"/>
                    <measurement group_id="O2" value="0.990" lower_limit="0.621" upper_limit="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 mins after start of product use (Day 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.28" lower_limit="0.985" upper_limit="1.66"/>
                    <measurement group_id="O2" value="1.34" lower_limit="0.866" upper_limit="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 mins after start of product use (Day 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.46" lower_limit="1.19" upper_limit="1.78"/>
                    <measurement group_id="O2" value="1.62" lower_limit="1.13" upper_limit="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 mins after start of product use (Day 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" lower_limit="1.21" upper_limit="1.75"/>
                    <measurement group_id="O2" value="1.67" lower_limit="1.13" upper_limit="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 mins after start of product use (Day 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.29" lower_limit="1.01" upper_limit="1.65"/>
                    <measurement group_id="O2" value="1.76" lower_limit="1.21" upper_limit="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr after start of product use (Day 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" lower_limit="1.01" upper_limit="1.33"/>
                    <measurement group_id="O2" value="1.71" lower_limit="1.29" upper_limit="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hr after start of product use (Day 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.927" lower_limit="0.726" upper_limit="1.18"/>
                    <measurement group_id="O2" value="1.16" lower_limit="0.784" upper_limit="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hr after start of product use (Day 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.530" lower_limit="0.360" upper_limit="0.782"/>
                    <measurement group_id="O2" value="0.551" lower_limit="0.361" upper_limit="0.840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Nicotine Concentration [cCmax]</title>
        <description>To measure the maximum plasma nicotine concentration [cCmax] following correction of baseline nicotine levels.</description>
        <time_frame>Derived from multiple blood sampling pre- and post-product use (over 4 hours post-product use), on day 1 and day 30.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>P3P-1mg</title>
            <description>Subjects randomized to exclusive use of P3P-1mg&#xD;
P3P-1mg: P3P-1mg (P3P product containing 1mg of nicotine.)</description>
          </group>
          <group group_id="O2">
            <title>P3P-2mg</title>
            <description>Subjects randomized to exclusive use of P3P-2mg&#xD;
P3P-2mg: P3P-2mg (P3P product containing 2mg of nicotine.)</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Nicotine Concentration [cCmax]</title>
          <description>To measure the maximum plasma nicotine concentration [cCmax] following correction of baseline nicotine levels.</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.46" lower_limit="1.12" upper_limit="1.89"/>
                    <measurement group_id="O2" value="2.11" lower_limit="1.62" upper_limit="2.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.05" lower_limit="1.69" upper_limit="2.48"/>
                    <measurement group_id="O2" value="2.39" lower_limit="1.73" upper_limit="3.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to the Maximum Nicotine Concentration [cTmax]</title>
        <description>To measure the time to maximum nicotine concentration [cTmax] following correction of baseline nicotine levels.</description>
        <time_frame>Derived from multiple blood sampling pre- and post-product use (over 4 hours post-product use), on day 1 and day 30.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>P3P-1mg</title>
            <description>Subjects randomized to exclusive use of P3P-1mg&#xD;
P3P-1mg: P3P-1mg (P3P product containing 1mg of nicotine.)</description>
          </group>
          <group group_id="O2">
            <title>P3P-2mg</title>
            <description>Subjects randomized to exclusive use of P3P-2mg&#xD;
P3P-2mg: P3P-2mg (P3P product containing 2mg of nicotine.)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to the Maximum Nicotine Concentration [cTmax]</title>
          <description>To measure the time to maximum nicotine concentration [cTmax] following correction of baseline nicotine levels.</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0" lower_limit="15.0" upper_limit="30.0"/>
                    <measurement group_id="O2" value="30.0" lower_limit="15.0" upper_limit="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="10.0" upper_limit="30.0"/>
                    <measurement group_id="O2" value="30.0" lower_limit="15.0" upper_limit="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve From Start of Product Use (T0) to 4 Hours [cAUC(0-4h)]</title>
        <description>To measure the area under the plasma concentration-time curve [cAUC(0-4h)] following correction of baseline nicotine levels.</description>
        <time_frame>Derived from multiple blood sampling pre- and post-product use (over 4 hours post-product use), on day 1 and day 30.</time_frame>
        <population>Some participants were excluded from analysis for protocol deviations. For participants in whom the elimination rate constant could not be calculated for any of the visits, background-corrected nicotine concentrations were considered as missing.</population>
        <group_list>
          <group group_id="O1">
            <title>P3P-1mg</title>
            <description>Subjects randomized to exclusive use of P3P-1mg&#xD;
P3P-1mg: P3P-1mg (P3P product containing 1mg of nicotine.)</description>
          </group>
          <group group_id="O2">
            <title>P3P-2mg</title>
            <description>Subjects randomized to exclusive use of P3P-2mg&#xD;
P3P-2mg: P3P-2mg (P3P product containing 2mg of nicotine.)</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Start of Product Use (T0) to 4 Hours [cAUC(0-4h)]</title>
          <description>To measure the area under the plasma concentration-time curve [cAUC(0-4h)] following correction of baseline nicotine levels.</description>
          <population>Some participants were excluded from analysis for protocol deviations. For participants in whom the elimination rate constant could not be calculated for any of the visits, background-corrected nicotine concentrations were considered as missing.</population>
          <units>ng*hour/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.03" lower_limit="2.34" upper_limit="3.92"/>
                    <measurement group_id="O2" value="4.74" lower_limit="3.64" upper_limit="6.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.96" lower_limit="3.29" upper_limit="4.78"/>
                    <measurement group_id="O2" value="5.35" lower_limit="3.85" upper_limit="7.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Craving for a Cigarette</title>
        <description>Measured on a Visual Analogue Scale (VAS) of 0 (no craving) to 100 (strong craving). Over time results calculated as area under curve mm*hour.</description>
        <time_frame>Before, during and up to 4 hours post-product use on day 1 and day 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>P3P-1mg</title>
            <description>Subjects randomized to exclusive use of P3P-1mg&#xD;
P3P-1mg: P3P-1mg (P3P product containing 1mg of nicotine.)</description>
          </group>
          <group group_id="O2">
            <title>P3P-2mg</title>
            <description>Subjects randomized to exclusive use of P3P-2mg&#xD;
P3P-2mg: P3P-2mg (P3P product containing 2mg of nicotine.)</description>
          </group>
        </group_list>
        <measure>
          <title>Craving for a Cigarette</title>
          <description>Measured on a Visual Analogue Scale (VAS) of 0 (no craving) to 100 (strong craving). Over time results calculated as area under curve mm*hour.</description>
          <units>score on a scale (millimetres*hour)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138" lower_limit="111" upper_limit="166"/>
                    <measurement group_id="O2" value="111" lower_limit="73.2" upper_limit="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130" lower_limit="99.1" upper_limit="160"/>
                    <measurement group_id="O2" value="109" lower_limit="68.6" upper_limit="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sensory Parameters</title>
        <description>Measured with a Sensory Questionnaire. Response to each question is assessed on a 7-point scale, ranging from 1 (not at all) to 7 (extremely).</description>
        <time_frame>Within 60 minutes after product use on day 1 and day 30.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>P3P-1mg</title>
            <description>Subjects randomized to exclusive use of P3P-1mg&#xD;
P3P-1mg: P3P-1mg (P3P product containing 1mg of nicotine.)</description>
          </group>
          <group group_id="O2">
            <title>P3P-2mg</title>
            <description>Subjects randomized to exclusive use of P3P-2mg&#xD;
P3P-2mg: P3P-2mg (P3P product containing 2mg of nicotine.)</description>
          </group>
        </group_list>
        <measure>
          <title>Sensory Parameters</title>
          <description>Measured with a Sensory Questionnaire. Response to each question is assessed on a 7-point scale, ranging from 1 (not at all) to 7 (extremely).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Puffs Evaluation/Liking (day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.33" lower_limit="2.82" upper_limit="3.85"/>
                    <measurement group_id="O2" value="3.50" lower_limit="2.87" upper_limit="4.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puffs Harshness (day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.60" lower_limit="4.09" upper_limit="5.11"/>
                    <measurement group_id="O2" value="5.18" lower_limit="4.74" upper_limit="5.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puffs Similar to Own Brand (day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.33" lower_limit="1.77" upper_limit="2.90"/>
                    <measurement group_id="O2" value="3.04" lower_limit="2.24" upper_limit="3.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puffs Strength on Tongue (day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="2.47" upper_limit="3.53"/>
                    <measurement group_id="O2" value="3.57" lower_limit="2.94" upper_limit="4.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puffs Strength in Nose (day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" lower_limit="1.40" upper_limit="2.20"/>
                    <measurement group_id="O2" value="2.07" lower_limit="1.71" upper_limit="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puffs Strength in Back of Mouth/Throat (day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.83" lower_limit="4.30" upper_limit="5.36"/>
                    <measurement group_id="O2" value="5.07" lower_limit="4.60" upper_limit="5.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puff Strength in Windpipe (day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.50" lower_limit="3.89" upper_limit="5.11"/>
                    <measurement group_id="O2" value="4.89" lower_limit="4.44" upper_limit="5.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puff Strength in Chest (day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.40" lower_limit="2.78" upper_limit="4.02"/>
                    <measurement group_id="O2" value="3.86" lower_limit="3.25" upper_limit="4.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puffs Evaluation/Liking (day 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.43" lower_limit="2.97" upper_limit="3.90"/>
                    <measurement group_id="O2" value="3.46" lower_limit="2.78" upper_limit="4.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puffs Harshness (day 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.20" lower_limit="3.67" upper_limit="4.73"/>
                    <measurement group_id="O2" value="4.68" lower_limit="4.15" upper_limit="5.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puffs Similar to Own Brand (day 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.93" lower_limit="2.25" upper_limit="3.61"/>
                    <measurement group_id="O2" value="2.64" lower_limit="2.04" upper_limit="3.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puffs Strength on Tongue (day 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.83" lower_limit="2.26" upper_limit="3.41"/>
                    <measurement group_id="O2" value="3.36" lower_limit="2.88" upper_limit="3.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puffs Strength in Nose (day 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" lower_limit="1.43" upper_limit="2.17"/>
                    <measurement group_id="O2" value="1.93" lower_limit="1.55" upper_limit="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puffs Strength in Back of Mouth/Throat (day 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.87" lower_limit="4.31" upper_limit="5.43"/>
                    <measurement group_id="O2" value="4.86" lower_limit="4.35" upper_limit="5.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puff Strength in Windpipe (day 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.20" lower_limit="3.54" upper_limit="4.86"/>
                    <measurement group_id="O2" value="4.93" lower_limit="4.45" upper_limit="5.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puff Strength in Chest (day 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.53" lower_limit="2.89" upper_limit="4.17"/>
                    <measurement group_id="O2" value="4.07" lower_limit="3.61" upper_limit="4.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Product Experience</title>
        <description>Measured with ABOUT[TM]-Product Experience questionnaire. Response to each question is assessed on a 7-point scale, ranging from 1 (not at all) to 7 (extremely).</description>
        <time_frame>Within 60 minutes after product use on day 1 and day 30.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>P3P-1mg</title>
            <description>Subjects randomized to exclusive use of P3P-1mg&#xD;
P3P-1mg: P3P-1mg (P3P product containing 1mg of nicotine.)</description>
          </group>
          <group group_id="O2">
            <title>P3P-2mg</title>
            <description>Subjects randomized to exclusive use of P3P-2mg&#xD;
P3P-2mg: P3P-2mg (P3P product containing 2mg of nicotine.)</description>
          </group>
        </group_list>
        <measure>
          <title>Product Experience</title>
          <description>Measured with ABOUT[TM]-Product Experience questionnaire. Response to each question is assessed on a 7-point scale, ranging from 1 (not at all) to 7 (extremely).</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Aversion (day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" lower_limit="1.08" upper_limit="1.42"/>
                    <measurement group_id="O2" value="1.32" lower_limit="1.12" upper_limit="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aversion (day 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.35" lower_limit="1.10" upper_limit="1.60"/>
                    <measurement group_id="O2" value="1.45" lower_limit="1.10" upper_limit="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Craving reduction (day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.23" lower_limit="3.65" upper_limit="4.82"/>
                    <measurement group_id="O2" value="4.04" lower_limit="3.38" upper_limit="4.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Craving reduction (day 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.07" lower_limit="3.47" upper_limit="4.66"/>
                    <measurement group_id="O2" value="4.14" lower_limit="3.56" upper_limit="4.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychological reward (day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="2.61" upper_limit="3.39"/>
                    <measurement group_id="O2" value="3.16" lower_limit="2.66" upper_limit="3.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychological reward (day 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.11" lower_limit="2.72" upper_limit="3.49"/>
                    <measurement group_id="O2" value="2.93" lower_limit="2.47" upper_limit="3.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Enjoyment of respiratory tract sensations (day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.13" lower_limit="1.58" upper_limit="2.69"/>
                    <measurement group_id="O2" value="2.29" lower_limit="1.65" upper_limit="2.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Enjoyment of respiratory tract sensations (day 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.33" lower_limit="1.81" upper_limit="2.86"/>
                    <measurement group_id="O2" value="2.29" lower_limit="1.70" upper_limit="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Product satisfaction (day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.70" lower_limit="3.26" upper_limit="4.14"/>
                    <measurement group_id="O2" value="3.62" lower_limit="3.10" upper_limit="4.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Product satisfaction (day 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.50" lower_limit="3.06" upper_limit="3.94"/>
                    <measurement group_id="O2" value="3.42" lower_limit="2.86" upper_limit="3.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Product Dependence</title>
        <description>Measured with ABOUT[TM]-Dependence questionnaire. Response to each question is assessed on a 5-point scale, ranging from 1 (not at all/never) to 5 (extremely/all the time) or a 6-point scale ranging from 0 (more than 3 hours) to 5 (0-5 minutes).</description>
        <time_frame>Within 60 minutes after product use on day 1 and day 30.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>P3P-1mg</title>
            <description>Subjects randomized to exclusive use of P3P-1mg&#xD;
P3P-1mg: P3P-1mg (P3P product containing 1mg of nicotine.)</description>
          </group>
          <group group_id="O2">
            <title>P3P-2mg</title>
            <description>Subjects randomized to exclusive use of P3P-2mg&#xD;
P3P-2mg: P3P-2mg (P3P product containing 2mg of nicotine.)</description>
          </group>
        </group_list>
        <measure>
          <title>Product Dependence</title>
          <description>Measured with ABOUT[TM]-Dependence questionnaire. Response to each question is assessed on a 5-point scale, ranging from 1 (not at all/never) to 5 (extremely/all the time) or a 6-point scale ranging from 0 (more than 3 hours) to 5 (0-5 minutes).</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Extent of use (day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.9" lower_limit="52.3" upper_limit="63.5"/>
                    <measurement group_id="O2" value="59.1" lower_limit="52.9" upper_limit="65.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extent of use (day 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.8" lower_limit="47.2" upper_limit="58.5"/>
                    <measurement group_id="O2" value="53.0" lower_limit="47.4" upper_limit="58.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Signs and symptoms (day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.2" lower_limit="42.1" upper_limit="48.4"/>
                    <measurement group_id="O2" value="49.5" lower_limit="45.7" upper_limit="53.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Signs and symptoms (day 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.3" lower_limit="33.7" upper_limit="43.0"/>
                    <measurement group_id="O2" value="41.1" lower_limit="37.4" upper_limit="44.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Behavioral impact (day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3" lower_limit="28.6" upper_limit="36.0"/>
                    <measurement group_id="O2" value="35.7" lower_limit="30.2" upper_limit="41.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Behavioral impact (day 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5" lower_limit="17.5" upper_limit="29.5"/>
                    <measurement group_id="O2" value="26.8" lower_limit="20.9" upper_limit="32.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Product Acceptance</title>
        <description>Measured with a Product Acceptance questionnaire. Response to each question is assessed on a 7-point scale, ranging from 1 (most negative) to 7 (most positive) or as multiple choice questions.</description>
        <time_frame>Within 60 minutes after product use on day 1 and day 30.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>P3P-1mg</title>
            <description>Subjects randomized to exclusive use of P3P-1mg&#xD;
P3P-1mg: P3P-1mg (P3P product containing 1mg of nicotine.)</description>
          </group>
          <group group_id="O2">
            <title>P3P-2mg</title>
            <description>Subjects randomized to exclusive use of P3P-2mg&#xD;
P3P-2mg: P3P-2mg (P3P product containing 2mg of nicotine.)</description>
          </group>
        </group_list>
        <measure>
          <title>Product Acceptance</title>
          <description>Measured with a Product Acceptance questionnaire. Response to each question is assessed on a 7-point scale, ranging from 1 (most negative) to 7 (most positive) or as multiple choice questions.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall opinion about P3P (day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.63" lower_limit="3.10" upper_limit="4.17"/>
                    <measurement group_id="O2" value="3.46" lower_limit="2.94" upper_limit="3.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall opinion about P3P (day 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.80" lower_limit="3.33" upper_limit="4.27"/>
                    <measurement group_id="O2" value="3.61" lower_limit="2.88" upper_limit="4.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taste intensity (day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.27" lower_limit="4.65" upper_limit="5.88"/>
                    <measurement group_id="O2" value="5.36" lower_limit="4.79" upper_limit="5.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taste intensity (day 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.03" lower_limit="4.36" upper_limit="5.70"/>
                    <measurement group_id="O2" value="5.25" lower_limit="4.52" upper_limit="5.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Consistency of sensation (day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.23" lower_limit="3.81" upper_limit="4.66"/>
                    <measurement group_id="O2" value="3.93" lower_limit="3.45" upper_limit="4.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Consistency of sensation (day 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.93" lower_limit="3.35" upper_limit="4.51"/>
                    <measurement group_id="O2" value="4.29" lower_limit="3.78" upper_limit="4.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Compared to pipe (day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" lower_limit="2.99" upper_limit="5.01"/>
                    <measurement group_id="O2" value="3.25" lower_limit="2.10" upper_limit="4.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Compared to pipe (day 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.77" lower_limit="3.06" upper_limit="4.47"/>
                    <measurement group_id="O2" value="3.90" lower_limit="2.71" upper_limit="5.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Compared to hookah (day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.28" lower_limit="2.54" upper_limit="4.02"/>
                    <measurement group_id="O2" value="3.24" lower_limit="2.36" upper_limit="4.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Compared to hookah (day 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.40" lower_limit="2.51" upper_limit="4.29"/>
                    <measurement group_id="O2" value="2.88" lower_limit="1.84" upper_limit="3.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Compared to heat-not-burn (day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.27" lower_limit="2.21" upper_limit="4.33"/>
                    <measurement group_id="O2" value="3.19" lower_limit="1.92" upper_limit="4.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Compared to heat-not-burn (day 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.06" lower_limit="2.06" upper_limit="4.06"/>
                    <measurement group_id="O2" value="4.13" lower_limit="2.99" upper_limit="5.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Compared to e-cigarette (day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.17" lower_limit="3.21" upper_limit="5.12"/>
                    <measurement group_id="O2" value="3.76" lower_limit="2.58" upper_limit="4.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Compared to e-cigarette (day 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.71" lower_limit="3.03" upper_limit="4.38"/>
                    <measurement group_id="O2" value="3.07" lower_limit="2.07" upper_limit="4.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Compared to snuff/chewing tobacco (day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" lower_limit="3.12" upper_limit="6.88"/>
                    <measurement group_id="O2" value="5.00" lower_limit="2.09" upper_limit="7.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Compared to snuff/chewing tobacco (day 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.56" lower_limit="2.01" upper_limit="5.10"/>
                    <measurement group_id="O2" value="4.83" lower_limit="2.59" upper_limit="7.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Compared to NRT (day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.40" lower_limit="5.29" upper_limit="7.51"/>
                    <measurement group_id="O2" value="5.67" lower_limit="3.21" upper_limit="8.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Compared to NRT (day 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.86" lower_limit="3.31" upper_limit="6.41"/>
                    <measurement group_id="O2" value="4.20" lower_limit="1.51" upper_limit="6.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Puffing Behavior of Subject</title>
        <description>To measure changes in subject puffing behavior. Evaluated by selection of one puffing behavior response out of three possible responses.&#xD;
1. Puffing and holding the aerosol in the mouth for a short time and then inhaling (i.e. like a cigarette)&#xD;
2. Puffing and immediately inhaling (without holding the aerosol in the mouth)&#xD;
3. Puffing and immediately exhaling, without inhalation</description>
        <time_frame>Evaluated by site staff on day 1 and day 30. Self-evaluated by subject on day 2, day 7, day 15, day 22, and day 29.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>P3P-1mg</title>
            <description>Subjects randomized to exclusive use of P3P-1mg&#xD;
P3P-1mg: P3P-1mg (P3P product containing 1mg of nicotine.)</description>
          </group>
          <group group_id="O2">
            <title>P3P-2mg</title>
            <description>Subjects randomized to exclusive use of P3P-2mg&#xD;
P3P-2mg: P3P-2mg (P3P product containing 2mg of nicotine.)</description>
          </group>
        </group_list>
        <measure>
          <title>Puffing Behavior of Subject</title>
          <description>To measure changes in subject puffing behavior. Evaluated by selection of one puffing behavior response out of three possible responses.&#xD;
1. Puffing and holding the aerosol in the mouth for a short time and then inhaling (i.e. like a cigarette)&#xD;
2. Puffing and immediately inhaling (without holding the aerosol in the mouth)&#xD;
3. Puffing and immediately exhaling, without inhalation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2: Inhalation Behavior #1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2: Behavior #2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2: Behavior #3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29: Behavior #1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29: Behavior #2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29: Behavior #3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Product Use</title>
        <description>To assess the number of any nicotine/tobacco products used overall on a daily basis.</description>
        <time_frame>Recorded daily by subject, in product use diary, from day 1 until day 30.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>P3P-1mg</title>
            <description>Subjects randomized to exclusive use of P3P-1mg&#xD;
P3P-1mg: P3P-1mg (P3P product containing 1mg of nicotine.)</description>
          </group>
          <group group_id="O2">
            <title>P3P-2mg</title>
            <description>Subjects randomized to exclusive use of P3P-2mg&#xD;
P3P-2mg: P3P-2mg (P3P product containing 2mg of nicotine.)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Product Use</title>
          <description>To assess the number of any nicotine/tobacco products used overall on a daily basis.</description>
          <units>products used per day</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>P3P</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.54" lower_limit="6.06" upper_limit="7.02"/>
                    <measurement group_id="O2" value="6.37" lower_limit="5.54" upper_limit="7.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cigarettes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.64" lower_limit="2.17" upper_limit="3.50"/>
                    <measurement group_id="O2" value="2.68" lower_limit="1.84" upper_limit="3.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heat not burn and/or smokeless tobacco</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" lower_limit="-0.09" upper_limit="0.61"/>
                    <measurement group_id="O2" value="0.25" lower_limit="-0.11" upper_limit="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other tobacco products</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" lower_limit="-0.02" upper_limit="0.06"/>
                    <measurement group_id="O2" value="0.01" lower_limit="-0.01" upper_limit="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Electronic cigarettes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.00" upper_limit="0.01"/>
                    <measurement group_id="O2" value="0.02" lower_limit="-0.01" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NEQ</title>
        <description>To measure percent changes from baseline in Nicotine equivalents (NEQ) concentrations, measured in spot urine and expressed as concentration adjusted for creatinine.</description>
        <time_frame>Measured at baseline, day 7, day 15, day 22, and day 29.</time_frame>
        <population>Some participants were excluded from analysis for protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>P3P-1mg</title>
            <description>Subjects randomized to exclusive use of P3P-1mg&#xD;
P3P-1mg: P3P-1mg (P3P product containing 1mg of nicotine.)</description>
          </group>
          <group group_id="O2">
            <title>P3P-2mg</title>
            <description>Subjects randomized to exclusive use of P3P-2mg&#xD;
P3P-2mg: P3P-2mg (P3P product containing 2mg of nicotine.)</description>
          </group>
        </group_list>
        <measure>
          <title>NEQ</title>
          <description>To measure percent changes from baseline in Nicotine equivalents (NEQ) concentrations, measured in spot urine and expressed as concentration adjusted for creatinine.</description>
          <population>Some participants were excluded from analysis for protocol deviations.</population>
          <units>Percent change from baseline</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3" lower_limit="-11.5" upper_limit="52.1"/>
                    <measurement group_id="O2" value="30.1" lower_limit="-16.7" upper_limit="76.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.6" lower_limit="-13.7" upper_limit="103"/>
                    <measurement group_id="O2" value="30.4" lower_limit="0.0291" upper_limit="60.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7" lower_limit="-16.0" upper_limit="99.3"/>
                    <measurement group_id="O2" value="18.8" lower_limit="-1.89" upper_limit="39.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.4" lower_limit="-12.4" upper_limit="65.1"/>
                    <measurement group_id="O2" value="22.9" lower_limit="-11.7" upper_limit="57.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total NNAL</title>
        <description>To measure percent changes from baseline in total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) concentrations, measured in spot urine and expressed as concentration adjusted for creatinine.</description>
        <time_frame>Measured at baseline, day 7, day 15, day 22, and day 29.</time_frame>
        <population>Some participants were excluded from analysis for protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>P3P-1mg</title>
            <description>Subjects randomized to exclusive use of P3P-1mg&#xD;
P3P-1mg: P3P-1mg (P3P product containing 1mg of nicotine.)</description>
          </group>
          <group group_id="O2">
            <title>P3P-2mg</title>
            <description>Subjects randomized to exclusive use of P3P-2mg&#xD;
P3P-2mg: P3P-2mg (P3P product containing 2mg of nicotine.)</description>
          </group>
        </group_list>
        <measure>
          <title>Total NNAL</title>
          <description>To measure percent changes from baseline in total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) concentrations, measured in spot urine and expressed as concentration adjusted for creatinine.</description>
          <population>Some participants were excluded from analysis for protocol deviations.</population>
          <units>Percent change from baseline</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.07" lower_limit="-46.9" upper_limit="32.8"/>
                    <measurement group_id="O2" value="-17.1" lower_limit="-36.3" upper_limit="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.05" lower_limit="-39.1" upper_limit="23.0"/>
                    <measurement group_id="O2" value="-5.75" lower_limit="-28.5" upper_limit="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" lower_limit="-27.9" upper_limit="56.4"/>
                    <measurement group_id="O2" value="-14.4" lower_limit="-33.6" upper_limit="4.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.10" lower_limit="-29.6" upper_limit="17.4"/>
                    <measurement group_id="O2" value="-11.8" lower_limit="-36.2" upper_limit="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CEMA</title>
        <description>To measure percent changes from baseline in 2-cyanoethylmercapturic acid (CEMA) concentrations, measured in spot urine and expressed as concentration adjusted for creatinine (ng/mg creat).</description>
        <time_frame>Measured at baseline, day 7, day 15, day 22, and day 29.</time_frame>
        <population>Some participants were excluded from analysis for protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>P3P-1mg</title>
            <description>Subjects randomized to exclusive use of P3P-1mg&#xD;
P3P-1mg: P3P-1mg (P3P product containing 1mg of nicotine.)</description>
          </group>
          <group group_id="O2">
            <title>P3P-2mg</title>
            <description>Subjects randomized to exclusive use of P3P-2mg&#xD;
P3P-2mg: P3P-2mg (P3P product containing 2mg of nicotine.)</description>
          </group>
        </group_list>
        <measure>
          <title>CEMA</title>
          <description>To measure percent changes from baseline in 2-cyanoethylmercapturic acid (CEMA) concentrations, measured in spot urine and expressed as concentration adjusted for creatinine (ng/mg creat).</description>
          <population>Some participants were excluded from analysis for protocol deviations.</population>
          <units>Percent change from baseline</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.1" lower_limit="-57.2" upper_limit="-18.8"/>
                    <measurement group_id="O2" value="-27.3" lower_limit="-44.4" upper_limit="-4.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.5" lower_limit="-55.7" upper_limit="-14.5"/>
                    <measurement group_id="O2" value="-26.0" lower_limit="-46.3" upper_limit="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.9" lower_limit="-43.2" upper_limit="15.7"/>
                    <measurement group_id="O2" value="-23.6" lower_limit="-46.8" upper_limit="9.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.3" lower_limit="-52.9" upper_limit="9.07"/>
                    <measurement group_id="O2" value="-30.8" lower_limit="-50.2" upper_limit="-3.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CYP2A6 Activity</title>
        <description>To measure percent change from baseline in CYP2A6 enzymatic activity, on day 30, as measured by molar metabolic ratio of trans-3-hydroxy-cotinine/cotinine in plasma.</description>
        <time_frame>Measured before product use, on day 1 and day 30.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>P3P-1mg</title>
            <description>Subjects randomized to exclusive use of P3P-1mg&#xD;
P3P-1mg: P3P-1mg (P3P product containing 1mg of nicotine.)</description>
          </group>
          <group group_id="O2">
            <title>P3P-2mg</title>
            <description>Subjects randomized to exclusive use of P3P-2mg&#xD;
P3P-2mg: P3P-2mg (P3P product containing 2mg of nicotine.)</description>
          </group>
        </group_list>
        <measure>
          <title>CYP2A6 Activity</title>
          <description>To measure percent change from baseline in CYP2A6 enzymatic activity, on day 30, as measured by molar metabolic ratio of trans-3-hydroxy-cotinine/cotinine in plasma.</description>
          <units>Percent change from baseline</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" lower_limit="-6.90" upper_limit="37.9"/>
                    <measurement group_id="O2" value="3.19" lower_limit="-13.0" upper_limit="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of Powder Extracted From P3P Used for PK Assessment.</title>
        <description>Weight difference (mg) of P3P before and after use, to determine the amount of powder extracted from P3P.</description>
        <time_frame>Before and after product use, on day 1 and day 30.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>P3P-1mg</title>
            <description>Subjects randomized to exclusive use of P3P-1mg&#xD;
P3P-1mg: P3P-1mg (P3P product containing 1mg of nicotine.)</description>
          </group>
          <group group_id="O2">
            <title>P3P-2mg</title>
            <description>Subjects randomized to exclusive use of P3P-2mg&#xD;
P3P-2mg: P3P-2mg (P3P product containing 2mg of nicotine.)</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Powder Extracted From P3P Used for PK Assessment.</title>
          <description>Weight difference (mg) of P3P before and after use, to determine the amount of powder extracted from P3P.</description>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1" lower_limit="20.7" upper_limit="27.4"/>
                    <measurement group_id="O2" value="22.4" lower_limit="19.2" upper_limit="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9" lower_limit="25.4" upper_limit="32.4"/>
                    <measurement group_id="O2" value="24.2" lower_limit="19.8" upper_limit="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the signature of the ICF by each subject until the end of the safety follow-up period, for a total study duration of up to 45 days for each subject.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>P3P-1mg</title>
          <description>Subjects randomized to exclusive use of P3P-1mg&#xD;
P3P-1mg: P3P-1mg (P3P product containing 1mg of nicotine.)</description>
        </group>
        <group group_id="E2">
          <title>P3P-2mg</title>
          <description>Subjects randomized to exclusive use of P3P-2mg&#xD;
P3P-2mg: P3P-2mg (P3P product containing 2mg of nicotine.)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (22.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Bilirubin Increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Throat Irritation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>We confirm we have the contractual provisions in place which specify that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.&#xD;
The Intellectual Property rights and research results from the present study belong to the Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christelle Haziza</name_or_title>
      <organization>Philip Morris Products S.A.</organization>
      <phone>+41 58 242 11 11</phone>
      <email>ClinicalTrials.PMI@pmi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

